FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer

February 14, 2018 -- The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news